IR501 data

IMNR announced that Phase II testing showed statistically significant improvements according to the ACR 20 criteria of the American College of Rheumatology. The low dose tested, 90 µg, was given to 31 patients,

Read the full 333 word article

How to gain access

Continue reading with a
two-week free trial.